Publication at Faculty of Medicine in Pilsen |
2023
Abstract
The prophylaxis of febrile neutropenia and keeping the relative dose intensity of chemotherapy, e.g. in the adjuvant treatment in breast cancer patients, is a very important issue. With the currently more widespread introduction of pegylated granulopoiesis growth factors (GCSF) for the prophylaxis of febrile neutropenia, the incidence of this complication in routine practice appears to be adequately lower.
Thera are chemotherapy-treated patients with metastatic castration-resistant prostate cancer and metastatic breast and lung cancer among the risk groups of patients, too.